TNSN05309A1 - Derives d'imidazole utilises comme antagonistes du recepteur du glutamate - Google Patents

Derives d'imidazole utilises comme antagonistes du recepteur du glutamate

Info

Publication number
TNSN05309A1
TNSN05309A1 TNP2005000309A TNSN05309A TNSN05309A1 TN SN05309 A1 TNSN05309 A1 TN SN05309A1 TN P2005000309 A TNP2005000309 A TN P2005000309A TN SN05309 A TNSN05309 A TN SN05309A TN SN05309 A1 TNSN05309 A1 TN SN05309A1
Authority
TN
Tunisia
Prior art keywords
receptor antagonists
imidazole derivatives
glutamate receptor
derivatives
mglur5 receptor
Prior art date
Application number
TNP2005000309A
Other languages
English (en)
Inventor
Bernd Buettelmann
Simona Maria Ceccarelli
Georg Jaeschke
Richard Hugh Philip Porter
Eric Vieira
Sabine Kolczewski
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TNSN05309A1 publication Critical patent/TNSN05309A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des dérivés imidazole qui sont des antagonistes du récepteur mGluR5, et qui sont représentés par la formule générale (I): dans laquelle R1, R2, R3 et R4 sont tels que définis dans le descriptif, un procédé permettant de produire ces dérivés, ainsi que des sels pharmaceutiquement acceptables servant à la préparation d'un médicament destiné au traitement ou à la prévention de troubles dans lesquels le récepteur mGluR5 intervient comme médiateur, tels que les troubles neurologiques aigus et/ou chroniques.
TNP2005000309A 2003-06-05 2005-12-01 Derives d'imidazole utilises comme antagonistes du recepteur du glutamate TNSN05309A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03012200 2003-06-05
PCT/EP2004/005881 WO2004108701A1 (fr) 2003-06-05 2004-06-01 Derives d'imidazole utilises comme antagonistes du recepteur du glutamate

Publications (1)

Publication Number Publication Date
TNSN05309A1 true TNSN05309A1 (fr) 2007-07-10

Family

ID=33483899

Family Applications (2)

Application Number Title Priority Date Filing Date
TNP2005000309A TNSN05309A1 (fr) 2003-06-05 2005-12-01 Derives d'imidazole utilises comme antagonistes du recepteur du glutamate
TNP2006000391A TNSN06391A1 (fr) 2003-06-05 2006-11-27 Pyridin-4-yl-ethynyl-imidazoles et pyrazoles, antagonistes du recepteur mglur5

Family Applications After (1)

Application Number Title Priority Date Filing Date
TNP2006000391A TNSN06391A1 (fr) 2003-06-05 2006-11-27 Pyridin-4-yl-ethynyl-imidazoles et pyrazoles, antagonistes du recepteur mglur5

Country Status (39)

Country Link
US (3) US7332510B2 (fr)
EP (1) EP1636206B1 (fr)
JP (1) JP4401384B2 (fr)
KR (1) KR100778948B1 (fr)
CN (1) CN100408572C (fr)
AR (1) AR044478A1 (fr)
AT (1) ATE377008T1 (fr)
AU (1) AU2004245208B2 (fr)
BR (1) BRPI0411095B8 (fr)
CA (1) CA2527315C (fr)
CL (1) CL2004001347A1 (fr)
CR (1) CR8094A (fr)
CY (1) CY1107856T1 (fr)
DE (1) DE602004009796T2 (fr)
DK (1) DK1636206T3 (fr)
EA (1) EA010577B1 (fr)
EC (1) ECSP056202A (fr)
ES (1) ES2294504T3 (fr)
GT (1) GT200400117A (fr)
HK (1) HK1093070A1 (fr)
HN (1) HN2004000208A (fr)
HR (1) HRP20070529T3 (fr)
IL (1) IL171930A (fr)
MA (1) MA27881A1 (fr)
MX (1) MXPA05013149A (fr)
MY (2) MY137272A (fr)
NO (1) NO332143B1 (fr)
NZ (1) NZ543637A (fr)
PA (1) PA8604101A1 (fr)
PE (1) PE20050162A1 (fr)
PL (1) PL1636206T3 (fr)
PT (1) PT1636206E (fr)
RS (1) RS53183B (fr)
SI (1) SI1636206T1 (fr)
TN (2) TNSN05309A1 (fr)
TW (1) TWI338007B (fr)
UA (1) UA80888C2 (fr)
WO (1) WO2004108701A1 (fr)
ZA (2) ZA200509807B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531529B2 (en) 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7452909B2 (en) 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
BRPI0511678A (pt) 2004-06-01 2008-01-08 Hoffmann La Roche piridin-4-il-etinil-imidazóis e pirazóis como antagonistas de receptor de mglu5
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
DE102006011574A1 (de) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
MY148217A (en) * 2006-12-21 2013-03-29 Hoffmann La Roche Polymorphs of a mglur5 receptor antagonist
US8334287B2 (en) * 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
US20120039999A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20140228398A1 (en) 2011-03-18 2014-08-14 Novartis Ag COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
AU2013333988B2 (en) * 2012-10-18 2017-03-09 F. Hoffmann-La Roche Ag Ethynyl derivatives as modulators of mGluR5 receptor activity
PE20150733A1 (es) * 2012-10-18 2015-05-17 Hoffmann La Roche Derivados de etinilo como moduladores de la actividad del receptor mglur5
EP3436009B1 (fr) * 2016-03-30 2024-03-06 Sinntaxis AB Modulateurs allostériques négatifs de mglur5 utiles dans le traitement de lésions du cerveau mature
CN116056701A (zh) * 2020-06-05 2023-05-02 诺埃玛制药公司 治疗结节硬化复合症的方法
MX2023001288A (es) * 2020-07-30 2023-04-28 Noema Pharma Ag Metodos de tratamiento de la neuralgia del trigemino.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0079312A3 (fr) 1981-11-11 1984-04-25 Ciba-Geigy Ag Composés d'acétylène hétérocycliques
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
AU780009B2 (en) * 1999-08-31 2005-02-24 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof
WO2002008205A1 (fr) * 2000-07-24 2002-01-31 Krenitsky Pharmaceuticals, Inc. 5-alkynyle pyrimidines substituees avec activite neurotrophique
KR100515549B1 (ko) * 2000-12-04 2005-09-20 에프. 호프만-라 로슈 아게 글루타메이트 수용체 길항제로서의 페닐에테닐 또는페닐에티닐 유도체
WO2003053922A2 (fr) * 2001-12-19 2003-07-03 Merck & Co., Inc. Imidazoles substitues par heteroaryle modulateurs du recepteur metabotropique du glutamate de type 5
WO2004038374A2 (fr) * 2002-10-24 2004-05-06 Merck & Co., Inc. Derives d'alcyne utilises comme marqueurs pour la liaison au recepteur du glutamate metabotropique
TWI292318B (en) * 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7091222B2 (en) * 2003-07-03 2006-08-15 Hoffmann-La Roche Inc. Imidazole derivatives

Also Published As

Publication number Publication date
DE602004009796D1 (de) 2007-12-13
UA80888C2 (en) 2007-11-12
JP4401384B2 (ja) 2010-01-20
EP1636206B1 (fr) 2007-10-31
PT1636206E (pt) 2008-01-28
MXPA05013149A (es) 2006-03-17
KR100778948B1 (ko) 2007-11-28
ECSP056202A (es) 2006-04-19
CN100408572C (zh) 2008-08-06
KR20060057537A (ko) 2006-05-26
US20080103306A1 (en) 2008-05-01
PE20050162A1 (es) 2005-03-22
US20040248888A1 (en) 2004-12-09
PA8604101A1 (es) 2004-12-16
CA2527315A1 (fr) 2004-12-16
JP2006526588A (ja) 2006-11-24
BRPI0411095B8 (pt) 2021-05-25
IL171930A (en) 2010-12-30
NZ543637A (en) 2008-04-30
US20080119489A1 (en) 2008-05-22
HRP20070529T3 (en) 2008-05-31
HN2004000208A (es) 2009-02-03
BRPI0411095B1 (pt) 2018-04-03
ES2294504T3 (es) 2008-04-01
EA010577B1 (ru) 2008-10-30
RS20050892A (en) 2007-12-31
AU2004245208A1 (en) 2004-12-16
RS53183B (en) 2014-06-30
GT200400117A (es) 2005-02-07
AR044478A1 (es) 2005-09-14
ATE377008T1 (de) 2007-11-15
WO2004108701A1 (fr) 2004-12-16
MY143353A (en) 2011-04-29
MY137272A (en) 2009-01-30
NO332143B1 (no) 2012-07-02
TW200509920A (en) 2005-03-16
CY1107856T1 (el) 2013-06-19
US7332510B2 (en) 2008-02-19
ZA200609681B (en) 2008-06-25
HK1093070A1 (en) 2007-02-23
MA27881A1 (fr) 2006-05-02
US7973165B2 (en) 2011-07-05
IL171930A0 (en) 2006-04-10
CR8094A (es) 2006-05-30
CN1802367A (zh) 2006-07-12
TNSN06391A1 (fr) 2008-02-22
CA2527315C (fr) 2010-08-10
PL1636206T3 (pl) 2008-04-30
EP1636206A1 (fr) 2006-03-22
CL2004001347A1 (es) 2005-05-06
BRPI0411095A (pt) 2006-07-18
NO20055465L (no) 2005-11-18
AU2004245208B2 (en) 2007-04-26
ZA200509807B (en) 2006-12-27
EA200501887A1 (ru) 2006-10-27
DE602004009796T2 (de) 2008-08-28
SI1636206T1 (sl) 2008-02-29
DK1636206T3 (da) 2008-02-11
TWI338007B (en) 2011-03-01
US8481548B2 (en) 2013-07-09

Similar Documents

Publication Publication Date Title
MA27881A1 (fr) Derives d'imidazole utilises comme antagonistes du recepteur du glutamate
MA31865B1 (fr) Dérivés isoxazolo-pyridine
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA27781A1 (fr) 3-fluoro-piperidines comme antagonistes de nmda/nr2b.
MA30722B1 (fr) Utilisation de derives de l'adenosine en tant qu'agonistes du recepteurs a2a
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA27575A1 (fr) Derives de 3-(3,5-dioxo-4,5-dihydro-3h-(1,2,4)triazine-2-yl)-benzamide servant d'inhibiteurs de p2x7 pour le traitement de maladies inflammatoires
MA31373B1 (fr) Composes amino-heterocycliques
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
MA30412B1 (fr) Composés Pharmaceutiques
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA27751A1 (fr) 4-phényltétrahydroisoquinolines substituées, procédé de production de ces composés, utilisation de ces composés en tant que médicaments et médicament contenant de tels composés
MA30693B1 (fr) Derives de la purine utilises en tant qu'agonistes de l'a2a
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
MA31754B1 (fr) Cis-imidazolines chirales
MA27569A1 (fr) Derives de pyrrolo-pyrazole substitues servant d'inhibiteurs de kinases
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
MA27726A1 (fr) Derives de 4-(4-(heterocyclylalkoxy)phenyl-1-(heterocyclyl-carbonyl) piperidine et composes associes servant d'antagonistes d'histamine h3 destines au traitement de troubles neurologiques
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
TWI265928B (en) A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw